KD PHARMA UK LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-05-10.

• ⚠

  Material uncertainty over going concern

  We draw attention to note 3 to the financial statements that describes the events and conditions that indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +50.3%

  £27,080,000 → £40,706,000

• Cash

  -42.2%

  £822,000 → £475,000

• Net assets

  -166%

  -£30,978,000 → -£82,410,000

• Employees

  -39%

  105 → 64

• Operating profit

  -24.5%

  -£30,375,000 → -£37,823,000

• Profit before tax

  -27.6%

  -£40,316,000 → -£51,432,000

• Wages

  -24.9%

  £4,646,000 → £3,489,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. KD PHARMA UK LIMITED 2019-05-10 → present
2. EPAX PHARMA UK LTD 2011-05-27 → 2019-05-10
3. TRYGG PHARMA UK LTD 2011-04-26 → 2011-05-27

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 3 to the financial statements that describes the events and conditions that indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.”

Significant events

• “Subsequent to the year end, as part of a wider O3 Group restructuring of operations, the company ceased production of Omega-3 products and changed its principal activity to the contract manufacture of small molecules.”
• “At the beginning of April 2025, as part of a wider restructuring of the O3 Group's global operations following the acquisition in 2024 of the Marine Lipids business from DSM-Firmenich AG, the company communicated to its employees a plan to cease the Omega 3 by the end of July 2025.”
• “On 6 January 2025, a fixed and floating charge was registered against the assets of the company as part of a wider O3 Group arrangement.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.